Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma

Mona S. Jahromi, Angelica R. Putnam, Colleen Druzgal, Jennifer Wright, Holly Spraker-Perlman, Michelle Kinsey, Holly Zhou, Kenneth M. Boucher, R. Lor Randall, Kevin B. Jones, David Lucas, Andrew Rosenberg, Dafydd Thomas, Stephen L. Lessnick, Joshua D. Schiffman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Ewing sarcoma (ES) is the second most common bone tumor in children and young adults, with dismal outcomes for metastatic and relapsed disease. To better understand the molecular pathogenesis of ES and to identify new prognostic markers, we used molecular inversion probes (MIPs) to evaluate copy number alterations (CNAs) and loss of heterozygosity (LOH) in formalin-fixed paraffin-embedded (FFPE) samples, which included 40 ES primary tumors and 12 ES metastatic lesions. CNAs were correlated with clinical features and outcome, and validated by immunohistochemistry (IHC). We identified previously reported CNAs, in addition to SMARCB1 (INI1/SNF5) homozygous loss and copy neutral LOH. IHC confirmed SMARCB1 protein loss in 7-10% of clinically diagnosed ES tumors in three separate cohorts (University of Utah [N = 40], Children's Oncology Group [N = 31], and University of Michigan [N = 55]). A multifactor copy number (MCN)-index was highly predictive of overall survival (39% vs. 100%, P < 0.001). We also identified RELN gene deletions unique to 25% of ES metastatic samples. In summary, we identified both known and novel CNAs using MIP technology for the first time in FFPE samples from patients with ES. CNAs detected by microarray correlate with outcome and may be useful for risk stratification in future clinical trials.

Original languageEnglish
Pages (from-to)391-404
Number of pages14
JournalCancer genetics
Volume205
Issue number7-8
DOIs
StatePublished - Jul 1 2012

Fingerprint

Molecular Probes
Ewing's Sarcoma
Loss of Heterozygosity
Paraffin
Formaldehyde
Immunohistochemistry
Gene Deletion
Young Adult
Neoplasms
Clinical Trials
Technology
Bone and Bones
Survival

Keywords

  • CEBPB
  • Copy number
  • Ewing sarcoma
  • Outcome
  • SMARCB1/INI1/SNF5

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Jahromi, M. S., Putnam, A. R., Druzgal, C., Wright, J., Spraker-Perlman, H., Kinsey, M., ... Schiffman, J. D. (2012). Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer genetics, 205(7-8), 391-404. https://doi.org/10.1016/j.cancergen.2012.05.012

Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. / Jahromi, Mona S.; Putnam, Angelica R.; Druzgal, Colleen; Wright, Jennifer; Spraker-Perlman, Holly; Kinsey, Michelle; Zhou, Holly; Boucher, Kenneth M.; Randall, R. Lor; Jones, Kevin B.; Lucas, David; Rosenberg, Andrew; Thomas, Dafydd; Lessnick, Stephen L.; Schiffman, Joshua D.

In: Cancer genetics, Vol. 205, No. 7-8, 01.07.2012, p. 391-404.

Research output: Contribution to journalArticle

Jahromi, MS, Putnam, AR, Druzgal, C, Wright, J, Spraker-Perlman, H, Kinsey, M, Zhou, H, Boucher, KM, Randall, RL, Jones, KB, Lucas, D, Rosenberg, A, Thomas, D, Lessnick, SL & Schiffman, JD 2012, 'Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma', Cancer genetics, vol. 205, no. 7-8, pp. 391-404. https://doi.org/10.1016/j.cancergen.2012.05.012
Jahromi MS, Putnam AR, Druzgal C, Wright J, Spraker-Perlman H, Kinsey M et al. Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer genetics. 2012 Jul 1;205(7-8):391-404. https://doi.org/10.1016/j.cancergen.2012.05.012
Jahromi, Mona S. ; Putnam, Angelica R. ; Druzgal, Colleen ; Wright, Jennifer ; Spraker-Perlman, Holly ; Kinsey, Michelle ; Zhou, Holly ; Boucher, Kenneth M. ; Randall, R. Lor ; Jones, Kevin B. ; Lucas, David ; Rosenberg, Andrew ; Thomas, Dafydd ; Lessnick, Stephen L. ; Schiffman, Joshua D. / Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. In: Cancer genetics. 2012 ; Vol. 205, No. 7-8. pp. 391-404.
@article{251df49c601a454ba1496875800de611,
title = "Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma",
abstract = "Ewing sarcoma (ES) is the second most common bone tumor in children and young adults, with dismal outcomes for metastatic and relapsed disease. To better understand the molecular pathogenesis of ES and to identify new prognostic markers, we used molecular inversion probes (MIPs) to evaluate copy number alterations (CNAs) and loss of heterozygosity (LOH) in formalin-fixed paraffin-embedded (FFPE) samples, which included 40 ES primary tumors and 12 ES metastatic lesions. CNAs were correlated with clinical features and outcome, and validated by immunohistochemistry (IHC). We identified previously reported CNAs, in addition to SMARCB1 (INI1/SNF5) homozygous loss and copy neutral LOH. IHC confirmed SMARCB1 protein loss in 7-10{\%} of clinically diagnosed ES tumors in three separate cohorts (University of Utah [N = 40], Children's Oncology Group [N = 31], and University of Michigan [N = 55]). A multifactor copy number (MCN)-index was highly predictive of overall survival (39{\%} vs. 100{\%}, P < 0.001). We also identified RELN gene deletions unique to 25{\%} of ES metastatic samples. In summary, we identified both known and novel CNAs using MIP technology for the first time in FFPE samples from patients with ES. CNAs detected by microarray correlate with outcome and may be useful for risk stratification in future clinical trials.",
keywords = "CEBPB, Copy number, Ewing sarcoma, Outcome, SMARCB1/INI1/SNF5",
author = "Jahromi, {Mona S.} and Putnam, {Angelica R.} and Colleen Druzgal and Jennifer Wright and Holly Spraker-Perlman and Michelle Kinsey and Holly Zhou and Boucher, {Kenneth M.} and Randall, {R. Lor} and Jones, {Kevin B.} and David Lucas and Andrew Rosenberg and Dafydd Thomas and Lessnick, {Stephen L.} and Schiffman, {Joshua D.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.cancergen.2012.05.012",
language = "English",
volume = "205",
pages = "391--404",
journal = "Cancer genetics",
issn = "2210-7762",
publisher = "Elsevier BV",
number = "7-8",

}

TY - JOUR

T1 - Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma

AU - Jahromi, Mona S.

AU - Putnam, Angelica R.

AU - Druzgal, Colleen

AU - Wright, Jennifer

AU - Spraker-Perlman, Holly

AU - Kinsey, Michelle

AU - Zhou, Holly

AU - Boucher, Kenneth M.

AU - Randall, R. Lor

AU - Jones, Kevin B.

AU - Lucas, David

AU - Rosenberg, Andrew

AU - Thomas, Dafydd

AU - Lessnick, Stephen L.

AU - Schiffman, Joshua D.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Ewing sarcoma (ES) is the second most common bone tumor in children and young adults, with dismal outcomes for metastatic and relapsed disease. To better understand the molecular pathogenesis of ES and to identify new prognostic markers, we used molecular inversion probes (MIPs) to evaluate copy number alterations (CNAs) and loss of heterozygosity (LOH) in formalin-fixed paraffin-embedded (FFPE) samples, which included 40 ES primary tumors and 12 ES metastatic lesions. CNAs were correlated with clinical features and outcome, and validated by immunohistochemistry (IHC). We identified previously reported CNAs, in addition to SMARCB1 (INI1/SNF5) homozygous loss and copy neutral LOH. IHC confirmed SMARCB1 protein loss in 7-10% of clinically diagnosed ES tumors in three separate cohorts (University of Utah [N = 40], Children's Oncology Group [N = 31], and University of Michigan [N = 55]). A multifactor copy number (MCN)-index was highly predictive of overall survival (39% vs. 100%, P < 0.001). We also identified RELN gene deletions unique to 25% of ES metastatic samples. In summary, we identified both known and novel CNAs using MIP technology for the first time in FFPE samples from patients with ES. CNAs detected by microarray correlate with outcome and may be useful for risk stratification in future clinical trials.

AB - Ewing sarcoma (ES) is the second most common bone tumor in children and young adults, with dismal outcomes for metastatic and relapsed disease. To better understand the molecular pathogenesis of ES and to identify new prognostic markers, we used molecular inversion probes (MIPs) to evaluate copy number alterations (CNAs) and loss of heterozygosity (LOH) in formalin-fixed paraffin-embedded (FFPE) samples, which included 40 ES primary tumors and 12 ES metastatic lesions. CNAs were correlated with clinical features and outcome, and validated by immunohistochemistry (IHC). We identified previously reported CNAs, in addition to SMARCB1 (INI1/SNF5) homozygous loss and copy neutral LOH. IHC confirmed SMARCB1 protein loss in 7-10% of clinically diagnosed ES tumors in three separate cohorts (University of Utah [N = 40], Children's Oncology Group [N = 31], and University of Michigan [N = 55]). A multifactor copy number (MCN)-index was highly predictive of overall survival (39% vs. 100%, P < 0.001). We also identified RELN gene deletions unique to 25% of ES metastatic samples. In summary, we identified both known and novel CNAs using MIP technology for the first time in FFPE samples from patients with ES. CNAs detected by microarray correlate with outcome and may be useful for risk stratification in future clinical trials.

KW - CEBPB

KW - Copy number

KW - Ewing sarcoma

KW - Outcome

KW - SMARCB1/INI1/SNF5

UR - http://www.scopus.com/inward/record.url?scp=84867145989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867145989&partnerID=8YFLogxK

U2 - 10.1016/j.cancergen.2012.05.012

DO - 10.1016/j.cancergen.2012.05.012

M3 - Article

C2 - 22868000

AN - SCOPUS:84867145989

VL - 205

SP - 391

EP - 404

JO - Cancer genetics

JF - Cancer genetics

SN - 2210-7762

IS - 7-8

ER -